Clinical Trial Update: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating first-line olomorasib with pembrolizumab, with or without chemotherapy, in advanced KRAS G12C-mutant non-small cell lung cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Olomorasib (olomorasib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | Phase 3 | Status: RECRUITING